United Therapeutics Buys Down Ralinepag Royalties for $525 Million

Nov 4, 2026 12:18 PM

View all comments（0）



United Therapeutics Corporation amended its exclusive license agreement for ralinepag with Arena Pharmaceuticals, a Pfizer subsidiary. Under the terms, United Therapeutics will pay $525 million upfront to completely eliminate all future low double-digit royalty obligations on net sales for all formulations of ralinepag, including both oral and inhaled versions.

AI-generated summary

United Therapeutics Corporation (Nasdaq: UTHR) announced that it entered into an amendment with Arena Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., concerning its exclusive license agreement for ralinepag.

Under the amendment, United Therapeutics will make an up-front payment of $525 million to eliminate all royalty obligations related to ralinepag. The royalty elimination covers all formulations of ralinepag, including oral and inhaled formulations.

The original agreement provided for a low double-digit royalty on United Therapeutics’ net sales of all ralinepag formulations.

This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Tesla and SpaceX Drop Over 4% in Overnight Trading: How Will Democratic Control of Congress Affect Musk's Companies?

TradingKey - The results of the 2026 US midterm elections have reshaped the balance of power in Congress. With the Democratic Party winning control of both the House of Representatives and the Senate, the Trump administration's policy leeway over the next two years will be further constrained. The new Congress will take office in January 2027, and businesses under Elon Musk may face heightened scrutiny.

Today’s Market Recap: AMD Surges Nearly 5% After Hours, AI Stock Rally Lifts Nasdaq, US Midterm Elections in Focus

TradingKey - On November 3, the three major U.S. stock indices closed mixed. A rebound in semiconductor and mega-cap tech stocks helped the Nasdaq snap a three-day losing streak, while Apple fell under the weight of its margin guidance, dragging the Dow slightly lower. In after-hours trading, AMD (A

KOSPI Rebounds Over 3% as SK Hynix Surges Over 5%; SoftBank Drops Over 4%

South Korea's KOSPI surged 3.07% in a strong V-shaped reversal, as Samsung Electronics and SK Hynix rallied more than 3%–5%, while Japanese stocks opened lower but found support from bargain hunting.

AMD Q3 Data Center Revenue Jumps 97% YoY, Driving 74% EPS Growth; Shares Surge 7% After Hours

On November 3, Eastern Time, AMD (AMD) reported its third-quarter financial results for fiscal year 2026. Data center revenue nearly doubled, driving record total revenue for the group, while adjusted earnings per share beat market expectations. The company expects fourth-quarter revenue growth to accelerate further, but free cash flow for the quarter was significantly below expectations, leaving the conversion of profit growth into cash flow an area to watch.

Nasdaq Snaps Three-Day Losing Streak, SOX Rises 2.6%; Chip Stocks Rebound Strongly, SpaceX Gains 3.6%

On November 3 Eastern Time, US stocks diverged on Tuesday. A rebound in chip stocks drove the Nasdaq and S&P 500 higher, while a drop in Apple weighed on the Dow. Investors stepped back into tech stocks following recent pressure while awaiting the results of the US midterm elections. At the close, the Dow Jones Industrial Average fell 0.38% to 51,786.72; the Nasdaq Composite Index rose 0.83% to 25,372.01; and the S&P 500 Index gained 0.36% to 7,568.92.

Featured Tools